Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Herbert is a French biotechnology company specializing in microbiome-based skincare solutions for inflammatory skin conditions. The company utilizes a proprietary postbiotic platform to develop treatments that restore the skin's microbial balance without the side effects associated with traditional antibiotics or steroids. Their product line includes targeted treatments for acne, eczema, and rosacea, all formulated based on clinical research into the skin's ecosystem. By focusing on the skin microbiome, Herbert aims to bridge the gap between high-end cosmetics and pharmaceutical dermatology. The company's approach centers on the use of non-living microbial components to modulate the skin's immune response and barrier function.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Herbert Skin Care.